Results 41 to 50 of about 56,167 (240)

Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents

open access: yesInternational Journal of Inflammation, 2021
Although there are undeniable advantages of treatment of the inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis, with biological agents, the increased susceptibility to tuberculosis should not be ignored.
Adam Krusiński   +5 more
doaj   +1 more source

Screening for tuberculosis of patients with HIV-infection. New possibilities

open access: yesActa Biomedica Scientifica, 2022
Background. Tuberculosis associated with HIV infection is becoming almost a new disease, where not only new approaches to treatment are being formed, but there is also a need to improve the quality and search for new means of early diagnosis of ...
E. A. Borodulina   +2 more
doaj   +1 more source

Establishment of a biosafe murine model of skeletal tuberculosis using Mycobacterium smegmatis

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This study developed a biosafe, accessible, and versatile murine model of bone TB using Mycobacterium smegmatis, a fast‐growing, nonpathogenic mycobacterial species with high genomic homology to Mycobacterium tuberculosis. Three infection routes—subperiosteal calvarial injection, intratibial injection, and intracardiac (left ventricular) inoculation ...
Yewei Jia   +12 more
wiley   +1 more source

Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis

open access: yesScientific Reports, 2019
Tuberculin skin test and interferon-gamma release assay are not good at differentiating active tuberculosis from latent tuberculosis. Interferon-gamma-induced protein 10 (IP-10) has been widely used to detect tuberculosis infection.
Xia Qiu   +7 more
doaj   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley   +1 more source

Prevalence and Risk Factors of Latent Tuberculosis Infection (LTBI) at Madura Boarding School as a High-Risk Congregate Setting

open access: yesJuxta: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Introduction: Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a highly contagious airborne disease. High-risk environments with frequent close interactions contribute to the spread of TB.
Muhammad Arif Ananto   +2 more
doaj   +1 more source

From Latent Tuberculosis Infection to Tuberculosis. News in Diagnosticsb (QuantiFERON-Plus) [PDF]

open access: yesPolish Journal of Microbiology, 2017
It is estimated that one third of the world’s population have latent tuberculosis infection and that this is a significant reservoir for future tuberculosis cases. Most cases occur within two years following initial infection. The identification of
Dagmara I. Borkowska   +5 more
doaj   +1 more source

Latent Tuberculosis Infection Care [PDF]

open access: yesClinical Infectious Diseases, 2022
Katherine M Gaskell   +6 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy